Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Coalition for Epidemic Preparedness Innovations (CEPI) and the University of Oxford announced the launch of a new project to initiate early development of prototype vaccines against the Junín virus. This is the first project to be initiated under CEPI and the University of Oxford’s strategic partnership to accelerate global pandemic preparedness efforts.

CEPI will provide up to $25 million to the University of Oxford to complete early development of prototype vaccines against the Junín virus, while also looking to improve manufacturing speed and scale-up of ChAdOx technology. The project will be led by Professor Teresa Lambe, Calleva Head of Vaccine Immunology and a Professor of Vaccinology & Immunology based in the Oxford Vaccine Group, and investigator at the Pandemic Sciences Institute.

The data and materials generated by this project could give the world a head start in rapidly developing safe and effective vaccines against Arenaviruses within 100 days of their identification, potentially stopping a future pandemic in its tracks. The learnings could be leveraged to inform vaccine design for related viruses from the Arenavirus family, giving the world a head start in rapidly responding to future outbreaks in as little as 100 days.

CEPI will support the preclinical and Phase I clinical development of a vaccine against the Junín virus using Oxford’s ChAdOx platform – the basis for Oxford’s COVID-19 vaccine, which saved 6.3 million lives in the first year of the global vaccine rollout – and other rapid response platforms. Endemic to the Pampas of South America, a large region of over a million square kilometers including Buenos Aires, the Junín virus causes Argentine Haemorrhagic Fever, with symptoms including muscular pain, dizziness, rashes, and a 15-30% case fatality.

Prof Lambe, said: ‘In this new project, scientists here in Oxford and in Latin America will develop and test candidate vaccines for Junín virus using both viral vector and mRNA technology. Our work will not only inform best-in-class vaccines against the Junín virus, but it will also support vaccine development for the broader group of Arenaviruses. It is this wider impact that could crucially help the world develop and manufacture safe, affordable vaccines at speed, preparing us for future pandemic threats.’

Junín virus: an example of the Arenavirus family

The Oxford team was able to develop a COVID-19 vaccine with unprecedented speed, in part because of their prior work to develop a vaccine against MERS which is a closely related virus from the coronavirus family. This gave the team a significant head start when COVID-19 emerged because they had solved many of the critical vaccinology problems for coronaviruses in advance.

CEPI and Oxford now aim to replicate this approach for the Arenavirus family by generating crucial knowledge about vaccine design and biological mechanisms linked to protection against the Junín virus which could significantly accelerate vaccine development against other viruses within the Arenavirus family. The viral family comprises New World Arenaviruses, a distinctive group within the Arenavirus family that includes viruses like Junín, as well as Old World Arenaviruses like Lassa fever, one of CEPI’s priority pathogens which are listed on the WHO R&D Blueprint as needing urgent R&D action.

Dr Richard Hatchett, CEO of CEPI said: ‘COVID-19 was a wake-up call to the world, highlighting the critical need to be better prepared for future viral threats. This new project will harness the University of Oxford’s extensive vaccinology experience and its innovative ChAdOx vaccine technology – one of only a handful of vaccine platforms proven to work at speed, scale, and low cost – to expand the world’s scientific knowledge on Arenavirus vaccines. The project will generate vital resources for the proposed Global Vaccine Library helping accelerate efforts to reduce vaccine development timelines to 100 days when faced with future threats.’s

The prototype vaccines, data, and knowledge about Arenaviruses that are generated through this research could make a vital contribution to the proposed Global Vaccine Library: a global repository of vaccine resources, capabilities, and data which can be pulled ‘off the shelf’ and quickly adapted in response to a future outbreak, accelerating the development of life-saving vaccines.

As part of the project, the team of scientists including Professors Teresa Lambe, Sandy Douglas, Thomas Brown, and Sue Ann Costa Clemens, will explore improving vaccine manufacturing processes to accelerate the speed and increase the scale of production of vaccines on their ChAdOx platform. The aim is to provide ‘proof-of-concept’ that the technology could dramatically accelerate vaccine development timelines from sequence to manufacturing of clinical trial materials, in alignment with the timeframes set out to achieve the 100 Days Mission for fast vaccine rollout during an outbreak.

Enabling equitable access

CEPI and the University of Oxford are committed to enabling equitable access to the outputs of this partnership in line with CEPI’s Equitable Access Policy so that vaccines are first available, at affordable prices, to populations when and where they are needed to end an outbreak or curtail an epidemic or pandemic, regardless of ability to pay. CEPI and the University of Oxford will also assess potential technology transfer to manufacturers in the Global South should the vaccine be successful in clinical trials.

Clinical trial data and results generated as part of this project will be published for open access for the benefit of the global scientific community.

This is the first project to be initiated under a strategic partnership between CEPI and the University of Oxford announced in August 2023. Through the partnership, CEPI will provide a total of up to US$80 million to support multiple projects in the design, manufacture, and vaccination strategies for globally accessible vaccines against known and unknown outbreak pathogens (Disease X) in pursuit of the 100 Days Mission. Embraced by the G7 and G20, the global goal aims to accelerate vaccine development timelines to a third of the time taken to develop COVID-19 vaccines. Additional projects which fall under the remit of the strategic partnership will be announced in the coming months.

Similar stories

Côte d’Ivoire becomes first nation to deploy R21 malaria vaccine

Côte d’Ivoire will become the first country to roll-out the new R21/Matrix-M™ vaccine with the first child vaccinated in Abidjan, marking a critical step and historic milestone in the global fight against malaria. 15 African countries are expected to introduce malaria vaccines with Gavi support in 2024, and countries plan to reach around 6.6 million children with the malaria vaccine in 2024 and 2025. The new vaccine has been authorised by Ghana, Nigeria, Burkina Faso and the Central African Republic, and many others are preparing to receive shipments.